INCLISIRAN

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Nucleic Acid Created by `admin` on `Sat Dec 16 10:10:57 GMT 2023` Edited by `admin` on `Sat Dec 16 10:10:57 GMT 2023`
Nucleic Acid Type	siRNA
Nucleic Acid Subtype
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	UOW2C71PG5
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

INCLISIRAN

Official Name

English

RNA, (AM-SP-(2'-DEOXY-2'-FLUORO)C-SP-AM-(2'-DEOXY-2'-FLUORO)A-(2'-DEOXY-2'-FLUORO)A-(2'-DEOXY-2'-FLUORO)A-GM-(2'-DEOXY-2'-FLUORO)C-AM-(2'-DEOXY-2'-FLUORO)A-AM-(2'-DEOXY-2'-FLUORO)A-CM-(2'-DEOXY-2'-FLUORO)A-GM-(2'-DEOXY-2'-FLUORO)G-UM-(2'-DEOXY-2'-FLUORO)

Systematic Name

English

LEQVIO

Brand Name

English

inclisiran [INN]

Common Name

English

ALN-60212

Code

English

DUPLEX OF ((2S,4R)-1-(1-((2-ACETAMIDO-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)-16,16-BIS((3-((3-(5-((2-ACETAMIDO-2-DEOXY-.BETA.-D-GALACTOPYRANOSYL)OXY)PENTANAMIDO)PROPYL)AMINO)-3-OXOPROPOXY)METHYL)-5,11,18-TRIOXO-14-OXA-6,10,17-TRIAZANONACOSAN-29-OYL)-4-HY

Systematic Name

English

INCLISIRAN [USAN]

Common Name

English

ALN-PCSSC

Code

English

Inclisiran [WHO-DD]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

618017

Created by admin on Sat Dec 16 10:10:57 GMT 2023 , Edited by admin on Sat Dec 16 10:10:57 GMT 2023

Code System Code Type Description

DRUG BANK

DB14901

Created by admin on Sat Dec 16 10:10:57 GMT 2023 , Edited by admin on Sat Dec 16 10:10:57 GMT 2023

PRIMARY

INN

10268

Created by admin on Sat Dec 16 10:10:57 GMT 2023 , Edited by admin on Sat Dec 16 10:10:57 GMT 2023

PRIMARY

RXCUI

2588243

Created by admin on Sat Dec 16 10:10:57 GMT 2023 , Edited by admin on Sat Dec 16 10:10:57 GMT 2023

PRIMARY

NCI_THESAURUS

C170062

Created by admin on Sat Dec 16 10:10:57 GMT 2023 , Edited by admin on Sat Dec 16 10:10:57 GMT 2023

PRIMARY

USAN

EF-47

Created by admin on Sat Dec 16 10:10:57 GMT 2023 , Edited by admin on Sat Dec 16 10:10:57 GMT 2023

PRIMARY

DAILYMED

UOW2C71PG5

Created by admin on Sat Dec 16 10:10:57 GMT 2023 , Edited by admin on Sat Dec 16 10:10:57 GMT 2023

PRIMARY

FDA UNII

UOW2C71PG5

Created by admin on Sat Dec 16 10:10:57 GMT 2023 , Edited by admin on Sat Dec 16 10:10:57 GMT 2023

PRIMARY

WIKIPEDIA

Inclisiran

Created by admin on Sat Dec 16 10:10:57 GMT 2023 , Edited by admin on Sat Dec 16 10:10:57 GMT 2023

PRIMARY

EVMPD

SUB182427

Created by admin on Sat Dec 16 10:10:57 GMT 2023 , Edited by admin on Sat Dec 16 10:10:57 GMT 2023

PRIMARY

CAS

1639324-58-5

Created by admin on Sat Dec 16 10:10:57 GMT 2023 , Edited by admin on Sat Dec 16 10:10:57 GMT 2023

PRIMARY

Sugar	Site Range	Site Count
Deoxyribose (DNA)	1_11	1 / 45
2'-O-Methyl-Ribose	1_1-1_6;1_8;1_10;1_12-1_22;2_1;2_3;2_7;2_9;2_11;2_13;2_15;2_17;2_19-2_23	32 / 45
2'-Fluoro-Ribose	1_7;1_9;2_2;2_4-2_6;2_8;2_10;2_12;2_14;2_16;2_18	12 / 45

Linkage	Site Range	Site Count
Phosporothioate	1_2-1_3;2_2-2_3;2_22-2_23	6 / 43
Phosphate	1_1;1_4-1_21;2_1;2_4-2_20	37 / 43

Related Record Type Details


					UPC6BTX7PY

INCLISIRAN SODIUM

SALT/SOLVATE -> PARENT

Amount:


					LGW95S5DG1

PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9

TARGET->INHIBITOR OF EXPRESSION

Comments:

Inhibits translation by targeting PCSK9 for degradation

Amount:

Related Record Type Details


					UOW2C71PG5

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
NUCLEOTIDE SUBSTITUTION	[1_22]	SITE_SPECIFIC	U		CEMDISIRAN, TERMINAL SUGAR MODIFICATION-	CQQ59545BV

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:SEQUNENCE(CALCULATED)	CHEMICAL